Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data

Basit Öğe Kaydı
dc.authorscopusid55542843700
dc.authorscopusid12794831300
dc.authorscopusid7004353906
dc.authorscopusid24536798400
dc.authorscopusid57225883776
dc.authorscopusid57203458191
dc.authorscopusid14422446100
dc.contributor.authorKimyon, G.
dc.contributor.authorKalyoncu, U.
dc.contributor.authorKiraz, S.
dc.contributor.authorBes, C.
dc.contributor.authorCoskun, N.
dc.contributor.authorYagiz, B.
dc.contributor.authorKucuksahin, O.
dc.date.accessioned2024-09-19T15:43:46Z
dc.date.available2024-09-19T15:43:46Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019, 2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEF (n=646, 42.3%; median follow up 35 months) or concomitant MTX (n=880, 57.3%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEF group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEF group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEF + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti–TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEF in combination with either anti-TNF or non-anti-TNF drugs appears as an effective and safe therapeutic option at least as MTX. © Copyright CliniCal and ExpErimEntal rhEumatology 2021.en_US
dc.description.sponsorshipHacettepe Rheumatology Societyen_US
dc.identifier.endpage858en_US
dc.identifier.issn0392-856X
dc.identifier.issue4en_US
dc.identifier.pmid32896266en_US
dc.identifier.scopus2-s2.0-85109656347en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage852en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14556
dc.identifier.volume39en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical and Experimental Rheumatology S.A.S.en_US
dc.relation.ispartofClinical and Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiologic or targeted-synthetic DMARDsen_US
dc.subjectLeflunomideen_US
dc.subjectMethotrexateen_US
dc.subjectRheumatoid arthritisen_US
dc.titleBiological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective dataen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu